ArticleJournal of gastrointestinal cancer2026
Factors Associated with Improved Survival for Stage I and II Pancreatic Adenocarcinoma Utilizing the National Cancer Database.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer related death in the United States. While Stage I and II PDAC represent the most treatable and potentially curative stages, most patients do not survive past 5 years of treatment. We sought to understand factors associated with long term survival in early-stage PDAC to improve outcomes and reduce disparities.
methodsThe National Cancer Database (NCDB) was queried for Stage I and II PDAC patients treated between 2012 and 2021. Patients were only included if they had a documented survival information. Comparisons between patients alive or deceased at 1, 3 and 5 years were evaluated using Wilcoxon, Chi-square, and Cochran-Armitage trend tests where appropriate. A multivariable Cox proportional hazards model (MVA) was used to evaluate factors associated with overall survival (OS).
resultsWe analyzed 43,398 patients with Stage I (n = 21,938) and Stage II (n = 21,460) PDAC. One-, three-, and five-year survival rates were 75.2%, 30.3%, and 12.8% for Stage I, and 68.6%, 23.4%, and 10.5% for Stage II, respectively. Across both stages, improved survival was significantly associated with younger age, lower Charlson-Deyo comorbidity score, Asian race, private insurance, higher income and education levels, and tumor location in the pancreatic body or tail (all p < 0.0001). Higher tumor grade, Black race, Medicaid or uninsured status, and treatment at community-level facilities were associated with significantly worse outcomes. Multivariable analysis confirmed these variables as independent predictors of one-, three-, and five-year survival. Despite early-stage diagnosis, marked disparities in long-term survival persisted based on race, insurance, and socioeconomic status.
conclusionLong-term survival for Stage I and II PDAC remains limited, despite diagnosis at an early and potentially curative stage. This highlights the need to not only focus on screening mechanisms for early diagnosis, but to address disparities and expand access to high-quality care that limit long term survival in this cohort. These results support ongoing investment in early detection, equitable treatment delivery, and research into tailored therapeutic strategies.
Indexed as
Identifiers
42530715What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.